Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2022-05-09 00:00:00 ET · period of report 2022-05-05 · accession 0001209191-22-027856 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-05-09 | 2022-05-05 | TARS | Ackermann Michael | Dir | P - Purchase | $13.50 | +100.0K | 100.0K | New | +$1.35M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-05 | P | A | 100,000 | $13.50 | 100,000 | I By the Ackermann & Elmen-Gruys Trust Dated June 24, 2014 | — | — | (F1) The Reporting Person purchased the shares of common stock reported hereby from the underwriters in an underwritten public offering conducted by the Issuer pursuant to an underwriting agreement, dated May 2, 2022, between the Issuer and the representatives of the several underwriters. Each share of common stock was sold by the underwriters at a price of $13.50 per share. (F2) The Reporting Person is the trustee of the Ackermann & Elmen-Gruys Trust Dated June 24, 2014 and has voting and dispositive power with respect to these shares. |